Diabetes Vaccine in Final Phase of FDA Approval

Diamyd is in the final phase (Phase III) of FDA drug approval for a Type 1 Diabetes vaccine. If this succeeds, it may put an end to new and recently diagnosed cases of Juvenile Diabetes! That's exciting news. I'm watching this stock in anticipation of the study findings.

The purpose of the study is to determine whether Diamyd® can preserve the body's own insulin producing capacity in persons recently diagnosed with type 1 diabetes. Maintaining the insulin producing capacity could result in simpler treatment and a better blood sugar balance, which in turn could reduce the risk of both short-term and long-term complications typically associated with diabetes.

Link: Diamyd Makes Investment in Time-to-market